<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35879519</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Cellular analysis of SOD1 protein-aggregation propensity and toxicity: a case of ALS with slow progression harboring homozygous SOD1-D92G mutation.</ArticleTitle><Pagination><StartPage>12636</StartPage><MedlinePgn>12636</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">12636</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-16871-3</ELocationID><Abstract><AbstractText>Mutations within Superoxide dismutase 1 (SOD1) cause amyotrophic lateral sclerosis (ALS), accounting for approximately 20% of familial cases. The pathological feature is a loss of motor neurons with enhanced formation of intracellular misfolded SOD1. Homozygous SOD1-D90A in familial ALS has been reported to show slow disease progression. Here, we reported a rare case of a slowly progressive ALS patient harboring a novel SOD1 homozygous mutation D92G (homD92G). The neuronal cell line overexpressing SOD1-D92G showed a lower ratio of the insoluble/soluble fraction of SOD1 with fine aggregates of the misfolded SOD1 and lower cellular toxicity than those overexpressing SOD1-G93A, a mutation that generally causes rapid disease progression. Next, we analyzed spinal motor neurons derived from induced pluripotent stem cells (iPSC) of a healthy control subject and ALS patients carrying SOD1-homD92G or heterozygous SOD1-L144FVX mutation. Lower levels of misfolded SOD1 and cell loss were observed in the motor neurons differentiated from patient-derived iPSCs carrying SOD1-homD92G than in those carrying SOD1-L144FVX. Taken together, SOD1-homD92G has a lower propensity to aggregate and induce cellular toxicity than SOD1-G93A or SOD1-L144FVX, and these cellular phenotypes could be associated with the clinical course of slowly progressive ALS.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sawamura</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imamura</LastName><ForeName>Keiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>iPSC-Based Drug-Discovery Cellular Basis Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical-Risk Avoidance Based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hikawa</LastName><ForeName>Rie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enami</LastName><ForeName>Takako</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical-Risk Avoidance Based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagahashi</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical-Risk Avoidance Based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamakado</LastName><ForeName>Hodaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichijo</LastName><ForeName>Hidenori</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujisawa</LastName><ForeName>Takao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minamiyama</LastName><ForeName>Sumio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaido</LastName><ForeName>Misako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sakai City Medical Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wada</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Karasuma Wada Clinic, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urushitani</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Haruhisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>iPSC-Based Drug-Discovery Cellular Basis Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical-Risk Avoidance Based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egawa</LastName><ForeName>Naohiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. naohiro@kuhp.kyoto-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. naohiro@kuhp.kyoto-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>iPSC-Based Drug-Discovery Cellular Basis Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan. naohiro@kuhp.kyoto-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. ryosuket@kuhp.kyoto-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>25</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35879519</ArticleId><ArticleId IdType="pmc">PMC9314329</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-16871-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-16871-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat. Rev. Neurosci. 2006;7:710&#x2013;723. doi: 10.1038/nrn1971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1971</ArticleId><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, et al. Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiol. Aging. 2016;39(219):e211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">26742954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama A, et al. Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiol. Aging. 2017;53(194):e191&#x2013;194.e198.</Citation><ArticleIdList><ArticleId IdType="pubmed">28160950</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Synofzik M, Fern&#xe1;ndez-Santiago R, Maetzler W, Sch&#xf6;ls L, Andersen PM. The human G93A SOD1 phenotype closely resembles sporadic amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2010;81:764&#x2013;767. doi: 10.1136/jnnp.2009.181719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.181719</ArticleId><ArticleId IdType="pubmed">20176600</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh YK, Shin KS, Yuan J, Kang SJ. Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells. J. Neurochem. 2008;104:993&#x2013;1005. doi: 10.1111/j.1471-4159.2007.05053.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05053.x</ArticleId><ArticleId IdType="pubmed">18233996</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Ezzi SA, Matsuo A, Tooyama I, Julien JP. The endoplasmic reticulum-Golgi pathway is a target for translocation and aggregation of mutant superoxide dismutase linked to ALS. FASEB J. 2008;22:2476&#x2013;2487. doi: 10.1096/fj.07-092783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.07-092783</ArticleId><ArticleId IdType="pubmed">18337461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata C, Morita M, Shibata N, Nakano I. Familial amyotrophic lateral sclerosis (FALS) with a novel SOD1 gene mutation: A clinicopathological study. Rinsho Shinkeigaku. 2007;47:211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17585602</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:69. doi: 10.1126/scitranslmed.aaf3962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3962</ArticleId><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TLE. Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin. Neurophysiol. 2008;119:497&#x2013;503. doi: 10.1016/j.clinph.2007.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Luisa Conforti Francesca, Sprovieri Teresa, Mazzei Rosalucia, Patitucci Alessandra, Ungaro Carmine, Zoccolella Stefano, Magariello Angela, Bella Vincenzo La, Tessitore Alessandro, Tedeschi Gioacchino, Simone Isa Laura, Majorana Giovanni, Valentino Paola, Citrigno Luigi, Gabriele Annalia, Bono Francesco, Monsurr&#xf2; Maria Rosaria, Muglia Maria, Quattrone Aldo. Further evidence that D90A-SOD1 mutation is recessively inherited in ALS patients in Italy. Amyotrophic Lateral Sclerosis. 2009;10(1):58&#x2013;60. doi: 10.1080/17482960802163853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802163853</ArticleId><ArticleId IdType="pubmed">18608106</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science (New York, N.Y.) 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F, Soucy G, Larivi&#xe8;re R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J. Neurochem. 2010;113:1188&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">20345765</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872. doi: 10.1016/j.cell.2007.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.019</ArticleId><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LX, et al. SOD1 mutation spectrum and natural history of ALS patients in a 15-year cohort in southeastern China. Front. Genet. 2021;12:746060. doi: 10.3389/fgene.2021.746060.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.746060</ArticleId><ArticleId IdType="pmc">PMC8551486</ArticleId><ArticleId IdType="pubmed">34721532</ArticleId></ArticleIdList></Reference><Reference><Citation>Boukaftane Y, et al. Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can. J. Neurol. Sci. 1998;25:192&#x2013;196. doi: 10.1017/S0317167100034004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0317167100034004</ArticleId><ArticleId IdType="pubmed">9706719</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward C, Brock DJ, Minns RA, Swingler RJ. Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J. Med. Genet. 1998;35:174. doi: 10.1136/jmg.35.2.174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.35.2.174</ArticleId><ArticleId IdType="pmc">PMC1051232</ArticleId><ArticleId IdType="pubmed">9556377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, et al. Marked reduction of the Cu/Zn superoxide dismutase polypeptide in a case of familial amyotrophic lateral sclerosis with the homozygous mutation. Neurosci. Lett. 2001;312:165&#x2013;168. doi: 10.1016/S0304-3940(01)02212-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)02212-1</ArticleId><ArticleId IdType="pubmed">11602336</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, et al. Phenotype in an infant with SOD1 homozygous truncating mutation. N. Engl. J. Med. 2019;381:486&#x2013;488. doi: 10.1056/NEJMc1905039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1905039</ArticleId><ArticleId IdType="pubmed">31314961</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, et al. SOD1 deficiency: A novel syndrome distinct from amyotrophic lateral sclerosis. Brain. 2019;142:2230&#x2013;2237. doi: 10.1093/brain/awz182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz182</ArticleId><ArticleId IdType="pmc">PMC6658856</ArticleId><ArticleId IdType="pubmed">31332433</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain. 1996;119(Pt 4):1153&#x2013;1172. doi: 10.1093/brain/119.4.1153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/119.4.1153</ArticleId><ArticleId IdType="pubmed">8813280</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MC, Haggarty SJ. Human pluripotent stem cell-derived models and drug screening in CNS precision medicine. Ann. N. Y. Acad. Sci. 2020;1471:18&#x2013;56. doi: 10.1111/nyas.14012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14012</ArticleId><ArticleId IdType="pmc">PMC8193821</ArticleId><ArticleId IdType="pubmed">30875083</ArticleId></ArticleIdList></Reference><Reference><Citation>Restagno G, et al. The IVS1 +319 t&gt;a of SOD1 gene is not an ALS causing mutation. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2005;6:45&#x2013;49. doi: 10.1080/14660820410021276a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410021276a</ArticleId><ArticleId IdType="pubmed">16036425</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, et al. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2013;31:458&#x2013;466. doi: 10.1002/stem.1293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.1293</ArticleId><ArticleId IdType="pubmed">23193063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>